retatrutide phase 2 trial weight loss Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a VisualAbstract: Retatrutide reduces body weight

Nutrition: Are you nourishing your bodynot just eating less or more, but meeting your energy and micronutrient needs

Phase 3 study This study was a 24-week double-blinded, randomized, placebo-controlled trial

It contains semaglutide as its active ingredient and is administered as a weekly injection

Gastrointestinal disorders were the most common adverse events with semaglutide, typically transient, of mild-to-moderate severity, occurring during dose escalation, and infrequently leading to treatment discontinuation

To better illustrate the multifaceted nature of semaglutide-associated biological influences on sexual desire, we use Fig